Objectives: (1) To compare tissue and plasma carotenoids status of healthy subjects and subjects with pre-cancer and cancer lesions; (2) to evaluate the effect of b-carotene supplementation on the concentrations of other carotenoids in tissue (luteine zeaxanthin, cryptoxanthin, lycopene, a-carotene) and in plasma and also retinol and a-tocopherol levels. Design: Eighteen subjects were divided into three groups on the basis of colonoscopy and histological analytical ®ndings: four healthy subjects (control group A); seven subjects affected by adenomatous polyps (group B with pre-cancer lesions); seven subjects suffering from colonic cancer (group C). Blood and colonic biopsy samples were taken (of colon and rectal mucosa) before and after b-carotene supplementation in all subjects. Groups A and B received a daily dose of b-carotene (30 mg/die) for 43 d. Group C's supplementation was terminated at the time which was performed, usually within 15 d. The tissue and plasma concentration of carotenoids, retinol and a-tocopherol were determined by high-performance liquid chromatography. Results: The tissue concentrations of each carotenoid were similar in all the intestinal sites examined as regards groups A and B, although there was a high degree of intra individual variability within each group. Only bcarotene made signi®cant increases (P`0.001) after supplementation. The subjects with cancer show tissue levels for each carotenoid lower than those of healthy subjects or subjects with polypous. The plasma levels of atocopherol did not change after supplementation while signi®cant increases were noted of retinol, a-carotene (P`0.01) and of b-carotene (P`0.001).
Introduction
Colorectal cancer is one of the most widespread forms of tumour in the world and its incidence has increased over the last ten years (National Cancer Institute, 1991) . Fifteen percent of the cancer diagnosed in the United States concerns large intestine carcinoma (National Cancer Institute, 1991) , and as such it is the second cause of cancer deaths.
Epidemiological studies have shown that some micronutrients with antioxidant action can modify oxidative stress and thus modulate the risk of degenerative illnesses (Duthie et al, 1989; O'Sullivan et al, 1991; Gey et al, 1987; Meydani et al, 1994) . A reduced risk of colorectal cancer has been described in subjects who take a high quantity of antioxidants (O'Sullivan et al, 1991; Schrober et al, 1987) as part of their diet. Among the various natural compounds with antioxidant action b-carotene (BC), vitamin C and vitamin E (Duthie et al, 1989; O'Sullivan et al, 1991; Gey et al, 1987; Meydani et al, 1994; Schrober et al, 1987 ) play a particularly important role. The real bene®t of b-carotene has been recently brought into question in the light of certain ®ndings (Heinonen et al, 1994) in which after supplementation, there was an increase in the mortality rate for some types of cancer (lung), even if the same authors do not refer data about colorectal cancer. However, other experimental studies have indicated a possible chemopreventive role of BC towards neoplasm in the gastrointestinal tract (Greenwald et al, 1990; Hennekens et al, 1994; Blot et al, 1993; Malone, 1991; Gerster, 1993) . This effect would seem to be linked to its speci®c antioxidant action as well as to the action of its metabolites (retinol and retinoic acid). Unfortunately, the literature offers little information on the correlation between the tissue levels of some carotenoids (lutein zeaxanthin, cryptoxanthin, lycopene, a-carotene and b-carotene) and colonic cancer. In addition the data on the plasma levels of vitamin E, after BC supplementation (Xu et al, 1992; Fontham et al, 1995) are contradictory.
The hypothesis is that in healthy subjects and adenomatous polyp carriers, tissue reserves of antioxidant can cope with the free radical charges that are produced by the body; therefore, it is suggested that during BC supplementation the reserves of the other carotenoids would be saturated and thereby reduce their request for and use of b-carotene. On the contrary where a pathology (carriers of colonic cancer) may be associated with an increased production of free radicals, the endogenous reserves of some carotenoids could be reduced.
The object of our study was to compare the tissue concentrations of luteine zeaxanthin, cryptoxanthin, lycopene, a-carotene and b-carotene in healthy subjects and in subjects with polypous or colonic cancer. Furthermore, we evaluated the behaviour of the plasma concentrations of these carotenoids, of a-tocopherol and of the retinol, before and after oral BC supplementation.
Materials and methods

Human subjects
Twenty healthy subjects, male and female volunteers, were recruited for the study. After clinical examination, colonoscopy exams and exclusion criteria (major gastrointestinal disorders such as ulcerative colitis, malabsorption or liver diseases) only eight subjects had normal colons as judged by colonoscopy. Of these only four subjects have completed the study. The patients with colonic polyps or colonic cancer were recruited at St.Vincenzo Hospital, which is af®liated with the Faculty of Medicine, the University of Rome, Italy. This study was approved by the St. Vincenzo Hospital internal (ethical committed) review board, and all subjects signed the appropriate informed consent under direct supervision of Prof G Pappalardo from the University of Rome, Italy.
The sample and the study protocols have been described in detail elsewhere (Maiani et al, 1995) . Eighteen subjects took part in the present study (8 men and 10 women), of which four healthy subjects represented the control group (Group A, aged 53 AE 13.7 y); seven subjects were affected by adenomatous polypous (Group B, age: 68.1 AE 10.2 y); and seven subjects were found to be affected by colonic cancer (Group C, age: 70.1 AE 10.5 y).
At the beginning of the study we used a checklist of food groups (such as fresh fruit, leafy, yellow and green vegetables and red wine) and in each group we have asked the frequency of food consumption over a week. We observed non-signi®cant differences in the consumption of fresh fruit and red wine in all groups. There were instead signi®cant differences (P`0.01) between consumption patterns of group A and group C: group A consumed leafy vegetables (such as lettuce, cabbage, spinach) 4.75 AE 0.96 times per week; yellow/green vegetables (such as pumpkin, carrots and French bean) 4.42 AE 1.71 times per week, group C consumed leafy vegetables 2.86 AE 0.90 times per week; yellow/green vegetables 2.28 AE 1.70 times per week. We have not checked if the individual appetite was decreased during the study. In our study only two subjects smoked 20 cigarettes per day, one in group A and one in group C.
During the study we have measured the weight (Kg), height (cm) and body fatness expressed as body mass index (BMI: Kg/m 2 ) of the subjects. We have not observed signi®cant differences among groups for all parameters considered.
Protocol of the study Subjects' blood was sampled before BC supplementation in order to evaluate the plasma concentrations of carotenoids, retinol and alpha-tocopherol. At the same time multiple biopsies were made, during endoscopy, at the level of the rectum and sigmoid colon (8 and 25 cm from anal verge) in all subjects in order to determine the tissue concentrations of the carotenoids (luteine zeaxanthin, cryptoxanthin, lycopene, a-carotene and BC). In patients with polypous and cancer, biopsies were also conducted on the neoplasmic tissue. The vitamin supplementation (oral daily dose of BC (30 mg/die; Hoffman Arove Spa, 2031 Milan-Italy), in group A and B, was terminated on day 43 when a new blood sample was taken to evaluate the concentrations of carotenoids, retinol and alpha-tocopherol, and a new colonoscopy conducted with biopsies at 8 and 25 cm (group A and B) and endoscopic polypectomy (group B). The period of six weeks of supplementation (42±43 d) was chosen because of our previous experience showing adequate accumulation of BC in plasma as well as colonic mucosa within a period of 4±8 wks , a longer period was not desirable because we wanted to remove the polypous as soon as possible in order to avoid missing any small cancer.
On the basis of these samples tissue concentrations were evaluated in all the foregoing carotenoids. In group C, supplementation (oral daily dose of BC (30 mg/die; Hoffman Arove Spa, 2031 Milan-Italy) terminated on day 15, when there was the histological con®rmation of a carcinoma. The con®rmation was followed by surgical resection and blood sampling.
Methodology
The subjects followed a diet without dross for three days before endoscopy and ingested a laxative pill 12 h before endoscopy. Tissue and blood were collected after an overnight fast and 43 d after initiating BC supplementation in group A and B and 15 d after initiation in group C. All of the tissues were cleaned and washed with saline solution to remove contaminating blood before analysis. The tissues were cut into pieces, weighted and stored at 770 C. The tissues were homogenised and saponi®ed by the addition of 107 N KOH and 2% pyrogallol in methanol and heating at 65 C for 60 min. Two extraction's were made of the mixture using 2 ml hexane and the hexane extracts then combined and washed with water to remove KOH. The plasma was extracted twice with hexane containing butylated hydroxytoluene (0.01% w/v). The samples (plasma and tissue) were dried and reconstituted.
The determination of the plasma (carotenoids, retinol and alpha-tocopherol) and tissue (carotenoids) concentrations were carried out by high performance liquid chromatography techniques (HPLC) fully described elsewhere (Maiani et al, 1995; Stacewicz-Sapuntzakis et al, 1987) . All measurements will be performed a duplicate assay. The results were expressed as ng/g wet weight for carotenoids in tissue and as mg/dl for carotenoids, retinol in plasma, while for a-tocopherol as mg/dl in plasma.
The laboratory of the Human Nutritional Unit participates in the international standard programme of the National Institute of Standards and Technology (NIST Gaithersburg, MD, USA). Therefore, the precision and the reproducibility of BC, retinol and alpha-tocopherol determinations have been evaluated with NIST USA reference material (SRM 968) and they come within the limits set for them, 7.9%, 7.6% and 6.3% respectively (expressed as variation coef®cients).
Statistical Analysis
The analysis of the data was conducted through the use of the following tests: parametric (`ANOVA' variance analysis and Paired T-test) and non parametric (Wilcoxon test and Mann Whitney U-test). One-way ANOVA has been used to test the differences among different tissues, while Wilcoxon test has been used to evaluate the differences in the same tissue before and after supplementation.
Results
Healthy (group A) and polyp carrier subjects (group B) were seen every four days at home, while cancer subjects (group C) were seen every day at Hospital for pill count and compliance assessment. There were no reported cases of toxicity and no complaints of skin discoloration or nausea. Compliance for b-carotene intake was very good (95± 100%). Table 1 shows the tissue concentrations (mean AE standard deviation) of studied carotenoids (luteine zeaxanthin, cryptoxanthin, lycopene, a-carotene and bcarotene) before and after oral BC supplementation. First of all, before and after supplementation a high inter-individual variability was noted in all the sites examined. In group A (Table 1 ) the tissue concentrations in luteine zeaxanthin and cryptoxanthin before supplementation are signi®cantly higher in the biopsies at 8 cm (rectum) with respect to those at 25 cm (colon), (respectively P`0.01 and P`0.05). After supplementation, the concentrations of carotenoids in the tissues under examination were not signi®cantly different from those observed before supplementation, with the exception of b-carotene (P`0.01) in the rectal mucosa. In adenomatous polypous carriers (group B) the tissue concentrations of cryptoxanthin (10.9 AE 13.0 ng/g wet weight of tissue) of the polypous tissue before supplementation were signi®cantly lower with respect to the tissue concentrations of intact tissue of the rectum (19.1 AE 25.6 ng/g wet weight; P`0.05) and of healthy tissue of the sigmoid colon (23.1 AE 39.6 ng/g wet weight; P`0.01). On the contrary, the lycopene levels are signi®cantly higher in the polypous tissue (14.3 AE 15.9 ng/g wet weight of tissue) with respect to the healthy tissue of the colon (9.4 AE 8.9 ng/g wet weight, P`0.05) and of the rectum (6.1 AE 2.1 ng/g wet weight of tissue, P`0.001). The tissue concentrations of other carotenoids, (luteine zeaxanthin, a and b-carotene) were similar in all the sites examined. After oral administration of b-carotene, the carotenoid levels failed to show any signi®cant variance in all the sites examined with respect to the base levels, except for the tissue concentrations of b-carotene which showed signi®cant increases (P`0.001) for rectal biopsies, (P`0.01) and for colon and polypous tissue biopsies.
In patients with colonic cancer (group C), a signi®cant difference was noted among tissue levels of both intact mucosa (rectum) of luteine zeaxanthin (P`0.05), a-carotene (P`0.05) and b-carotene (P`0.01), and the cancer tissue before and after supplementation. Signi®cant differences were not noticeable with respect to other carotenoids studied. Table 1 and Table 2 also compare the carotenoid levels in the three groups before and after supplementation. The levels of carotenoids other than b-carotene in group A and B tissues are similar before and after b-carotene supplementation. In group C the levels of luteine zeaxanthin, acarotene and b-carotene before supplementation are signi®cantly lower, at the level of 8 cm biopsies (healthy tissue, rectum) with respect to healthy subjects (P`0.05) and with respect to polypous group (P`0.01). The levels of lutein plus zeaxanthin, cryptoxanthin, a-carotene and bcarotene in the cancer tissue are statistically lower in respect to healthy and carrier polypous subjects as shown in Table 1 and Table 2 . These differences persisted after supplementation. Table 3 set out the average plasma levels of carotenoids, retinol and a-tocopherol before and after BC supplementation. Before supplementation, the plasma levels of luteine zeaxanthin, a-carotene and BC were signi®cantly lower in patients with colonic cancer than those of healthy subjects (P`0.01) and those with polypous (P`0.01). The f,g P`0.01; h,l P`0.001; i,l P`0.05. Wilcoxon test before and after supplementation: *P`0.05; **P`0.01; ***P`0.001.
Plasma and tissue carotenoid levels after b b-carotene supplementation G Pappalardo et al same trend was observed in plasma concentrations of retinol and a-tocopherol; namely signi®cantly lower in patients with cancer than in healthy subjects (P`0.001) and in subjects with polypous (P`0.001). After supplementation, a modest increase was noted in group A in levels of luteine zeaxanthin and a-carotene (P`0.05) and a signi®cant increase in BC (P`0.001) and in retinol (P`0.01). On the other hand, no signi®cant variations were noted in cryptoxanthin and lycopene concentrations. In group B, statistically signi®cant variations were observed in the plasma levels of a-carotene (P`0.05), BC (P`0.001) and retinol (P`0.05). In the patients of group C statistically signi®cant (P`0.001) differences exist only for the levels of a-carotene and BC. In conclusion, no group exhibits signi®cant variations as regards the plasma levels of a-tocopherol after oral BC supplementation.
Discussion and conclusions
In our study we evaluated the tissue levels of some carotenoids (luteine zeaxanthin, cryptoxanthin, lycopene, a-and b-carotene) before and after supplementation with oral doses of b-carotene (30 mg/die) for 43 d. At the plasma level we evaluated, besides the carotenoids cited above also retinol and a-tocopherol. The latter was analysed in order to evaluate the variations of the circulating plasma levels both before and after b-carotene supplementation. A ®rst observation concerns the high inter-individual variability of the plasma and tissue concentrations both before and after oral BC supplementation. This is a phenomenon described in the literature and is, probably, to be related to a series of physiological factors, such as age, mastication, food preparations, cooking, the presence of changes in intestinal¯ora, changed intestinal absorption and the presence of gastritis (Maiani et al, 1989a; Ames et al, 1993; Jonsson, 1991) . The combination of such factors could explain high inter-individual variability which is found at both tissue and plasma levels.
In our study we discovered that in healthy subjects and polypous carriers the tissue levels of the various carotenoids did not change after b-carotene supplementation, except for b-carotene which increased signi®cantly after oral administration (Maiani et al, 1995) . On the contrary in subjects with colorectal cancer a signi®cant increase in the tissue levels (of both the healthy and carcinomatose mucose) of luteine zeaxanthin and a-carotene as well as an increase in b-carotene levels after supplementation. The increase in luteine zeaxanthin and a-carotene concentrations for the subjects of the group C could be interpreted as a saving effect of BC towards these carotenoids, considering the reduced antioxidant capacities of patients with Plasma and tissue carotenoid levels after b b-carotene supplementation G Pappalardo et al carcinoma, as shown by the low basic plasma values of the carotenoids, the retinol and the a-tocopherol of these subjects when compared with the other two groups. In addition in patients with carcinoma, the increase of plasma and tissue BC following supplementation is less than that of healthy subjects or carriers of polypous. Some studies have reported that oral b-carotene supplementation reduces the plasma levels of luteine, while increasing the plasma levels of lycopene and a-carotene (Wahlqvist et al, 1994; Micozzi et al, 1992; Kostic et al, 1995) . Other studies indicate a reduction in the plasma concentration of a-tocopherol after BC supplementation (Xu et al, 1992; Bowen et al, 1993; Phillips et al, 1993; Shklar et al, 1993) , while others failed to demonstrate these interactions (Fontham et al, 1995; Willet et al, 1983; Mobarhan et al, 1990) . However, all studies found an increase in a-carotene. This could be due to the fact that BC supplementation would interfere with the metabolism of the other carotenoids, retinoids and with vitamin E Leitner et al, 1986) . Our study demonstrated that after supplementation the plasma levels of a-tocopherol were similar to the base values, and plasma retinol increase which was found could be explained by the partial conversion of BC into vitamin A (Simpson & Chichester, 1981) .
BC supplementation brings about a statistically signi®-cant increase in plasma concentrations of a-carotene in the three groups of subjects. The high pressure liquid chromatography analysis in the present study of the b-carotene capsules did not indicate the presence of a-carotene. As has been suggested by Walquist et al, 1994 the carotenoid hydrocarbons such as lycopene, a-and b-carotene, may have a different absorption path with respect to carotene containing oxygen (xanthophyll) such as luteine, zeaxanthin and cryptoxanthin. However, this hypothesis does not explain the increase in a-carotene which we found in the plasma of our subjects following supplementation. A reduced metabolic utilisation of a-carotene in the presence of large quantities of b-carotene, which has a higher bioavailability, could be the best explanation for the high levels of a-carotene observed. In subjects with carcinoma, the effect could be enhanced by a saving of a-carotene due to the utilisation of a b-carotene supplement on the part of an organism with depleted antioxidant reserves.
Conclusion
The patients with colonic cancer seem to exhibit a signi®cant reduction in their carotenoids reserves with respect to normal subjects, and its re-consolidation after supplementation does not bring it back to normal values. At present it is not possible to establish if this reduction is the cause or the effect of the onset of cancer. In addition, we can state that b-carotene oral supplementation leads to an increase in plasma a-carotene in all groups. The accumulation of b-carotene in the neoplastic tissues may have signi®cant therapeutic importance to reduce the rate of cell proliferation (Cahill et al, 1993; Phillips et al, 1993) and tumor metastasis or even enhancing the effects of chemotherapeutic agents. However the negative or deleterious effects have not yet been ruled out and further studies are indicated.
